KR970703152A - 치료제 용도의 피리딜비스인산염(pyridylbisphosphonates for use as a therapeutical agent) - Google Patents

치료제 용도의 피리딜비스인산염(pyridylbisphosphonates for use as a therapeutical agent) Download PDF

Info

Publication number
KR970703152A
KR970703152A KR1019960706991A KR19960706991A KR970703152A KR 970703152 A KR970703152 A KR 970703152A KR 1019960706991 A KR1019960706991 A KR 1019960706991A KR 19960706991 A KR19960706991 A KR 19960706991A KR 970703152 A KR970703152 A KR 970703152A
Authority
KR
South Korea
Prior art keywords
pyridinyl
methylidene
amino
bisphosphate
tetraethyl ester
Prior art date
Application number
KR1019960706991A
Other languages
English (en)
Other versions
KR100363692B1 (ko
Inventor
마르자나 헤이킬라-호이카
한누 니칸데르
리타 한누니에미
레나 라우렌
테르투 크렐이몰라
시르피 리우코-시피
칼레르보 바난넨
라이자 셀만
Original Assignee
포스티 유하니, 카우마 칼레비
한누니에미 리트바
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포스티 유하니, 카우마 칼레비, 한누니에미 리트바 filed Critical 포스티 유하니, 카우마 칼레비
Publication of KR970703152A publication Critical patent/KR970703152A/ko
Application granted granted Critical
Publication of KR100363692B1 publication Critical patent/KR100363692B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)

Abstract

본 발명은 임의의 고리 치환된 피리디닐아미노메틸리덴비스인산테트라알킬 에스테르(1) 및 악성 종양에 의한 용골성 골 질환, 파제트병과 일차 및 이차 골다공증과 같은 골 질환을 치료하는 그의 용도에 관한 것이다.

Description

치료제 용도의 피리딜비스인산염(PYRIDYLBISPHONATES FOR USE AS A THERAPEUTICAL AGENT)
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 치료 활성제 용도를 갖는 다음 일반식(1)의 피리디닐-아미노메틸리덴비스인 산테트라에스테르:
    식 중에서, 각각의 R1∼R4기는 곧은 또는 가지친 사슬의 포화 C1∼C5-알킬기이며, 각각의 X 및 Y는 독립적으로 수소이거나, 곧은 또는 가지친 포화 C1∼C5-알킬기, 할로겐, 히드록시, C1∼C5-알콕시, 벤질록시, 아실록시, 니트로, 트리플루오르메틸기 또는 NR5R6이며, 여기서 R5및 R6은 동일하거나 상이한 수소, C1∼C5-알킬기 또는 아실기임.
  2. 제1항에 있어서, 알콕시 및 아실기에서의 알킬기를 포함한 C1∼C5-알킬기가 메틸 또는 에틸을 나타내는 것이며, 할로겐이 염소를 나타내는 것인 치료 활성제 용도를 갖는 일반식 (1)의 화합물.
  3. 제1항 또는 제2항에 있어서, R1∼R4기가 동일하며, 바람직하게는 에틸인 치료 활성제 용도를 갖은 화합물.
  4. 제3항에 있어서, 피리디닐기가 2-피리디닐인 치료 활성제 용도를 갖은 화합물.
  5. 제1항에 있어서, [(2-피리디닐아미노)메틸리덴]비스인산테트라에틸에스테르, [[(3-히드록시-2-피리디닐)아미노]메틸리덴]비스인산테트라에틸에스테르, [[(6-에톡시-3-피리디닐)아미노]메틸리덴]비스인산테트라에틸에스테르, [(4-피리디닐아미노)메틸리덴비스인산데트라에틸에스테르, [[(5-클로로-2-피리디닐)아미노]메틸리덴]비스인산테트라에틸에스테르, [[(5-메톡시-2-피리디닐)아미노]메틸리덴]비스인산테트라에틸에스데르, [[(6-아미노-2-피리디닐)아미노]메틸리덴]비스인산테트라에틸에스테르, [[(3-니트로-2-피리디닐)아미노]메틸리덴]비스인산테트라에틸에스테르, [[(3,5-디클로로-2-피리디닐)아미노]메틸리덴]비스인산테트라에틸에스테르, [[(6-히드록시-3-피리디닐)아미노]메틸리덴]비스인산테트라에틸에스테르, [[(5-히드록시-2-피리디닐)아미노]메틸리덴]비스인산데트라에틸에스테르, [[(3-클로로-5-트리플루오르메틸-피리디닐)아미노)메틸리덴]비스인산테트라에틸에스테르, [[(2-클로로-3-피리디닐)아미노]메틸리덴]비스인산테트라에틸에스테르, [[(6-클로로-3-피리디닐)아미노]메틸리덴]비스인산테트라에틸에스테르, [[(3-벤질록시-2-피리디닐)아미노]메틸리덴]비스인산테트라에틸에스테르, [[(5-니트로-2-피리디닐)아미노]메틸리덴]비스인산테트라에틸에스테르, 또는[[(5-벤질록시-2-피리디닐)아미노]메틸리덴]비스인산테트라에틸에스테르인 치료 활성제 용도의 화합물.
  6. 전술한 항 중 어느 한 항에 있어서, 악성 종양에 의한 용골성 골 질환, 파제트병과 일차 및 이차 골다공증과 같은 골 질환을 치료하는 용도의 화합물.
  7. 제1∼5항 중 어느 한 항에 따른 화합물과 의약적으로 허용되는 담체를 함유하는 것을 특징으로 하는 악성 종양에 의한 용골성 골 질환, 파제트병 일차 및 이차 골다공증과 같은 골 질환 치료용 의약적인 조성물.
  8. 악성 종양에 의한 용골성 골 질환, 파제트병과 일차 및 이차 골다공증과 같은 골 질환을 치료하기 위한 의약적인 조성물의 제조를 위한 활성 제제로서의, 제1∼5항에 중 어느 한 항에 의한 화합물의 용도.
  9. 제1∼5항에 중 어느 한 항에 의한 화합물 또는 제7항에 의한 조성물의 유효량을 악성 종양에 의한 용골성 골 질환, 파제트병과 일차 및 이차 골다공증과 같은 골 질환에 걸린 포유류에게 투여함으로써, 악성 종양에 의한 용골성 골 질환, 파제트병과 일차 및 이차 골다공증과 같은 골 질환을 치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960706991A 1994-06-09 1995-06-02 치료제용도의피리딜비스인산염 KR100363692B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9402001A SE9402001D0 (sv) 1994-06-09 1994-06-09 Pyridylbisphosphonates for use as a therapeutical agent
SE9402001-3 1994-06-09

Publications (2)

Publication Number Publication Date
KR970703152A true KR970703152A (ko) 1997-07-03
KR100363692B1 KR100363692B1 (ko) 2003-02-07

Family

ID=20394303

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960706991A KR100363692B1 (ko) 1994-06-09 1995-06-02 치료제용도의피리딜비스인산염

Country Status (27)

Country Link
US (2) US5866556A (ko)
EP (1) EP0762883B1 (ko)
JP (1) JP3883137B2 (ko)
KR (1) KR100363692B1 (ko)
CN (1) CN1077792C (ko)
AT (1) ATE208622T1 (ko)
AU (1) AU691616B2 (ko)
BG (1) BG63104B1 (ko)
BR (1) BR9508185A (ko)
CZ (1) CZ291477B6 (ko)
DE (1) DE69523914T2 (ko)
DK (1) DK0762883T3 (ko)
EE (1) EE03475B1 (ko)
ES (1) ES2162919T3 (ko)
HK (1) HK1012572A1 (ko)
HU (1) HU228618B1 (ko)
IS (1) IS1801B (ko)
NO (1) NO311069B1 (ko)
NZ (1) NZ287094A (ko)
PL (1) PL180705B1 (ko)
PT (1) PT762883E (ko)
RO (1) RO119433B1 (ko)
RU (1) RU2154482C2 (ko)
SE (1) SE9402001D0 (ko)
SK (1) SK282650B6 (ko)
UA (1) UA43918C2 (ko)
WO (1) WO1995033466A1 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL351674A1 (en) * 1999-05-21 2003-05-19 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
US20020103161A1 (en) 1999-12-17 2002-08-01 Manfred Weigele Novel heterocycles
IL150062A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Proton pump inhibitors
IL150059A0 (en) * 1999-12-17 2002-12-01 Ariad Pharma Inc Novel heterocycles
US20040014726A1 (en) * 2000-10-27 2004-01-22 Thua Osterman Method for the preparation of a pharmaceutical composition, and its use
EP1482897A2 (en) * 2002-02-19 2004-12-08 Ilex Products, Inc. Aminodiphosphonate apolipoprotein e modulators
TW200413381A (en) * 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US20050010305A1 (en) * 2003-01-28 2005-01-13 Lee Francis Y. Novel bone graft composite
US20050065171A1 (en) * 2003-06-25 2005-03-24 Shakespeare William C. Substituted purine derivatives
JP2005060303A (ja) * 2003-08-12 2005-03-10 Sutaagen:Kk 不動性骨粗鬆の治療または予防剤
US7862552B2 (en) * 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US447256A (en) * 1891-02-24 Apparatus for flashing and exhausting incandescent electric lamps
US4447256A (en) * 1977-07-20 1984-05-08 Nissan Chemical Industries, Ltd. N-(Unsubstituted or substituted pyridyl)aminomethylene-diphosphonic acids, herbicidal compositions containing same, their use for herbicides, and process for preparing same
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
HU199151B (en) * 1987-03-10 1990-01-29 Yamanouchi Pharma Co Ltd Process for producing bis-phosphonic acid derivatives
EP0282309A3 (en) * 1987-03-11 1990-03-14 Yamanouchi Pharmaceutical Co. Ltd. Azole-aminomethylene bisphosphonic acid derivatives

Also Published As

Publication number Publication date
US5866556A (en) 1999-02-02
CN1077792C (zh) 2002-01-16
JPH10500977A (ja) 1998-01-27
NO965228D0 (no) 1996-12-06
DE69523914D1 (en) 2001-12-20
NZ287094A (en) 1998-04-27
BR9508185A (pt) 1997-08-12
KR100363692B1 (ko) 2003-02-07
WO1995033466A1 (en) 1995-12-14
US6083938A (en) 2000-07-04
EE9600191A (et) 1997-06-16
ATE208622T1 (de) 2001-11-15
PL317612A1 (en) 1997-04-14
JP3883137B2 (ja) 2007-02-21
DK0762883T3 (da) 2002-03-11
NO965228L (no) 1996-12-06
AU691616B2 (en) 1998-05-21
EP0762883B1 (en) 2001-11-14
PL180705B1 (pl) 2001-03-30
EP0762883A1 (en) 1997-03-19
IS4392A (is) 1996-12-02
DE69523914T2 (de) 2002-06-27
HU228618B1 (en) 2013-04-29
IS1801B (is) 2002-01-22
CZ291477B6 (cs) 2003-03-12
RO119433B1 (ro) 2004-11-30
NO311069B1 (no) 2001-10-08
AU2569895A (en) 1996-01-04
UA43918C2 (uk) 2002-01-15
BG63104B1 (bg) 2001-04-30
CN1149830A (zh) 1997-05-14
ES2162919T3 (es) 2002-01-16
CZ356196A3 (en) 1997-07-16
BG101116A (en) 1998-03-31
EE03475B1 (et) 2001-08-15
SK282650B6 (sk) 2002-10-08
HK1012572A1 (en) 1999-08-06
HUT75525A (en) 1997-05-28
SE9402001D0 (sv) 1994-06-09
PT762883E (pt) 2002-05-31
SK157296A3 (en) 1997-06-04
RU2154482C2 (ru) 2000-08-20
HU9603375D0 (en) 1997-01-28

Similar Documents

Publication Publication Date Title
AU2014224111B2 (en) Positively charged water-soluble prodrugs of 1H-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
LU90956I2 (fr) Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique
JP6112867B2 (ja) サキシトキシン誘導体での触覚の喪失の処置
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
MY127082A (en) Synergistic methods and compositions for treating cancer
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
MA27129A1 (fr) Les pyrrolopyrimidines en tant qu'inhibiteurs du kinase de proteine.
KR970703152A (ko) 치료제 용도의 피리딜비스인산염(pyridylbisphosphonates for use as a therapeutical agent)
ATE269865T1 (de) Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren
PT1039900E (pt) Agentes terapeuticos
RU97100161A (ru) Использование пиридилбифосфонатов в качестве терапевтического средства
AU2002357191A1 (en) Derivatives of isoindigo, indigo and indirubin and use in treating cancer
KR950016760A (ko) 치질 치료제
ES2181849T3 (es) Procedimiento para minimizar la perdida osea.
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
RU2005105693A (ru) Применение алкилфосфохолинов и лекарственное средство для лечения опухолевых заболеваний
KR960034190A (ko) N-아실피페라진 유도체 및 항균제, 항궤양제
KR960700711A (ko) 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases)
BR0308293A (pt) Terapia à base de estatina para aumentar a manutenção cognitiva
ATE293602T1 (de) 2-aminopyridine als inhibitoren von cyclooxygenase-2
RU99118510A (ru) Композиция для лечения или предупреждения рака простаты

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121114

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20131031

Year of fee payment: 12

EXPY Expiration of term